Loading
Latest filing published 12 Feb 2026 for Avadel Pharmaceuticals PLC, €389k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by Naseem Amin span 2 companies, the busiest being Bellerophon Therapeutics, Inc. and Avadel Pharmaceuticals PLC. Between 28 April 2016 and 12 February 2026, the trades on record add up to 12 filings.
No open-market sale appears; the market trades are 3 purchases worth €354k. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 8 share grants.
Most recently, on 12 February 2026, the filings show a transaction worth €389k in Avadel Pharmaceuticals PLC. The last insider purchase was made public on 25 January 2019, 2,829 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations